To validate the INT-MI series molecular data and assess whether HER2 inhibition by trastuzumab affects ERBB2, FASN, and CD36 transcript levels, we analyzed a gene expression dataset of matched core biopsies (n = 17) collected from HER2 + BC patients enrolled in the TRUP window-of-opportunity trial before and after one cycle of trastuzumab monotherapy (Fig. 1B) [31]. This evidence concerns the gene FASN and breast cancer.